Neil S. Belloff
General Counsel presso ACORDA THERAPEUTICS, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Neil S.
Belloff is currently the Secretary & General Counsel at Acorda Therapeutics, Inc. He previously worked as the Senior Corporate Counsel at Celgene Corp.
and as the Executive VP, US Corporate & Securities Counsel at Deutsche Telekom AG.
From 2020 to 2021, he served as the COO, Secretary, EVP & General Counsel at Eloxx Pharmaceuticals, Inc. Mr. Belloff completed his undergraduate studies at Queens College and his graduate studies at New York University.
He also obtained a graduate degree from Quinnipiac University School of Law.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 24/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Neil S. Belloff
| Società | Posizione | Inizio |
|---|---|---|
| ACORDA THERAPEUTICS, INC. | General Counsel | 08/11/2021 |
Precedenti posizioni note di Neil S. Belloff
| Società | Posizione | Fine |
|---|---|---|
| ELOXX PHARMACEUTICALS, INC. | Chief Operating Officer | 25/08/2021 |
| CELGENE | Corporate Officer/Principal | - |
| DEUTSCHE TELEKOM AG | Corporate Officer/Principal | - |
Formazione di Neil S. Belloff
| Queens College | Undergraduate Degree |
| New York University | Graduate Degree |
| Quinnipiac University School of Law | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| DEUTSCHE TELEKOM AG | Communications |
| ACORDA THERAPEUTICS, INC. | Health Technology |
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Borsa valori
- Insiders
- Neil S. Belloff
